Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RGLS's Cash to Debt is ranked higher than
75% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. RGLS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RGLS' s Cash to Debt Range Over the Past 10 Years
Min: 1.76  Med: 8.90 Max: No Debt
Current: No Debt
Equity to Asset 0.88
RGLS's Equity to Asset is ranked higher than
79% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RGLS: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
RGLS' s Equity to Asset Range Over the Past 10 Years
Min: -1.26  Med: 0.72 Max: 0.89
Current: 0.88
-1.26
0.89
F-Score: 4
Z-Score: 8.02
M-Score: -2.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -403.24
RGLS's Operating margin (%) is ranked lower than
69% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. RGLS: -403.24 )
Ranked among companies with meaningful Operating margin (%) only.
RGLS' s Operating margin (%) Range Over the Past 10 Years
Min: -585.6  Med: -99.01 Max: -51.76
Current: -403.24
-585.6
-51.76
Net-margin (%) -500.71
RGLS's Net-margin (%) is ranked lower than
72% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. RGLS: -500.71 )
Ranked among companies with meaningful Net-margin (%) only.
RGLS' s Net-margin (%) Range Over the Past 10 Years
Min: -739.08  Med: -137.07 Max: -55.13
Current: -500.71
-739.08
-55.13
ROE (%) -57.81
RGLS's ROE (%) is ranked lower than
67% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. RGLS: -57.81 )
Ranked among companies with meaningful ROE (%) only.
RGLS' s ROE (%) Range Over the Past 10 Years
Min: -169.02  Med: -50.28 Max: -24
Current: -57.81
-169.02
-24
ROA (%) -48.15
RGLS's ROA (%) is ranked lower than
67% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. RGLS: -48.15 )
Ranked among companies with meaningful ROA (%) only.
RGLS' s ROA (%) Range Over the Past 10 Years
Min: -38.49  Med: -29.62 Max: -16.48
Current: -48.15
-38.49
-16.48
ROC (Joel Greenblatt) (%) -2002.35
RGLS's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. RGLS: -2002.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RGLS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1544.17  Med: -531.03 Max: -450.68
Current: -2002.35
-1544.17
-450.68
» RGLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RGLS Guru Trades in

RGLS Guru Trades in

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
Q3 2015

RGLS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.51
RGLS's P/B is ranked higher than
55% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 2.68 vs. RGLS: 2.51 )
Ranked among companies with meaningful P/B only.
RGLS' s P/B Range Over the Past 10 Years
Min: 2.34  Med: 4.00 Max: 12.91
Current: 2.51
2.34
12.91
P/S 21.03
RGLS's P/S is ranked lower than
70% of the 1121 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. RGLS: 21.03 )
Ranked among companies with meaningful P/S only.
RGLS' s P/S Range Over the Past 10 Years
Min: 0.11  Med: 20.65 Max: 113.71
Current: 21.03
0.11
113.71
Current Ratio 9.24
RGLS's Current Ratio is ranked higher than
71% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. RGLS: 9.24 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 8.24 Max: 12.36
Current: 9.24
1.64
12.36
Quick Ratio 9.24
RGLS's Quick Ratio is ranked higher than
72% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. RGLS: 9.24 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 8.24 Max: 12.36
Current: 9.24
1.64
12.36
Days Sales Outstanding 8.40
RGLS's Days Sales Outstanding is ranked higher than
90% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. RGLS: 8.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.47  Med: 7.26 Max: 13.04
Current: 8.4
1.47
13.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.76
RGLS's Price/Net Cash is ranked higher than
73% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: 6.04 vs. RGLS: 2.76 )
Ranked among companies with meaningful Price/Net Cash only.
RGLS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.04  Med: 4.68 Max: 8.92
Current: 2.76
3.04
8.92
Price/Net Current Asset Value 2.61
RGLS's Price/Net Current Asset Value is ranked higher than
74% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: 6.40 vs. RGLS: 2.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RGLS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.87  Med: 4.50 Max: 8.11
Current: 2.61
2.87
8.11
Price/Tangible Book 2.50
RGLS's Price/Tangible Book is ranked higher than
67% of the 1048 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. RGLS: 2.50 )
Ranked among companies with meaningful Price/Tangible Book only.
RGLS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.75  Med: 4.30 Max: 7.38
Current: 2.5
2.75
7.38
Price/Median PS Value 0.99
RGLS's Price/Median PS Value is ranked lower than
58% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. RGLS: 0.99 )
Ranked among companies with meaningful Price/Median PS Value only.
RGLS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.03 Max: 4.54
Current: 0.99
0.01
4.54
Earnings Yield (Greenblatt) (%) -39.08
RGLS's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. RGLS: -39.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGLS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -46.4  Med: 0.00 Max: 0
Current: -39.08
-46.4
0

More Statistics

Revenue(Mil) $14
EPS $ -1.42
Beta1.34
Short Percentage of Float25.39%
52-Week Range $5.23 - 21.22
Shares Outstanding(Mil)52.34

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 20 7 7 42
EPS($) -1.04 -1.10 -1.35 -0.97
EPS without NRI($) -1.04 -1.10 -1.35 -0.97

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:7RG.Germany,
Regulus Therapeutics Inc. was incorporated in the State of Delaware. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The Company was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Isis Pharmaceuticals, Inc., or Isis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. microRNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. The Company benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. The Company has exclusive rights to over 900 patents and patent applications pertaining to oligonucleotide modifications, conjugates, and design patterns, all for use in targeting microRNA for therapeutic applications. The microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat human disease. It is currently optimizing anti-miRs targeting miR-21, miR-122, miR-33 and miR-10b for development candidate selection. It has established strategic alliances with AstraZeneca, GSK and Sanofi and it will continue to seek partners who can bring therapeutic expertise, development and commercialization capabilities and funding to allow it to maximize the potential of its microRNA product platform. Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those it is developing.
» More Articles for NAS:RGLS

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Hovnanian Enterprises Inc, Regulus Therapeutics Inc, Monster Beverage Co Apr 27 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
This Week’s Pharma Highlights Mar 19 2015 
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe S Feb 01 2015 

More From Other Websites
3 Key FDA Decisions Expected in February Jan 31 2016
Regulus Completes RG-101 Enrollment in Phase II Combination Study Jan 21 2016
Regulus Completes RG-101 Enrollment in Phase II Combination Study Jan 21 2016
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and... Jan 12 2016
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Other Events Jan 08 2016
Regulus Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Jan 06 2016
Regulus Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Jan 06 2016
Regulus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : January 1, 2016 Jan 01 2016
Biotechnology Equities Ahead of Market -- Regulus Therapeutics, Ocata Therapeutics, Vanda Pharma,... Dec 30 2015
Regulus Therapeutics: Strong Industry, Solid Earnings Estimate Revisions Dec 24 2015
Regulus Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
Pre-Market Pulse on Biotechnology Stocks -- Inovio Pharma, Vital Therapies, Regulus Therapeutics,... Dec 21 2015
RG-125(AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 Being Developed for the Treatment... Dec 18 2015
RG-125(AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 Being Developed for the Treatment... Dec 18 2015
Is Regulus Therapeutics Inc (RGLS) Going to Burn These Hedge Funds? Dec 13 2015
REGULUS THERAPEUTICS INC. Financials Dec 08 2015
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 08 2015
Regulus Appoints Joseph P. Hagan Chief Operating Officer Dec 07 2015
Regulus Appoints Joseph P. Hagan Chief Operating Officer Dec 07 2015
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK